Study #2017-0512
Evaluation Of Ruxolitinib And Thalidomide Combination As A Therapy For Patients With Myelofibrosis
MD Anderson Study Status
Not Accepting
Treatment Agent
Ruxolitinib, Thalidomide
Description
The purpose of this study is to test any good and bad effects of the study drugs called ruxolitinib and thalidomide. Ruxolitinib and thalidomide could shrink the cancer, but it could also cause side effects.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Myelofibrosis
Study phase:
Phase II
Physician name:
Prithviraj Bose
Department:
Leukemia
For general questions about clinical trials:
1-855-404-4637
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.